NDAORALSOLUTION
Approved
Mar 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MYCIFRADIN (neomycin sulfate) by Pfizer is clinical pharmacology neomycin sulfate is poorly absorbed from the normal gastrointestinal tract. First approved in 2009.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYCIFRADIN (neomycin sulfate) is an oral aminoglycoside antibiotic that suppresses intestinal bacterial growth by inhibiting bacterial protein synthesis. It is poorly absorbed from the gastrointestinal tract, with approximately 97% eliminated unchanged in feces, making it suitable for local bowel decontamination. The drug is effective primarily against gram-negative bacilli and some gram-positive organisms, with onset of bacterial suppression occurring rapidly and persisting 48-72 hours.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating declining commercial focus and potential consolidation of brand team resources.
Mechanism of Action
CLINICAL PHARMACOLOGY Neomycin sulfate is poorly absorbed from the normal gastrointestinal tract.The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function. The unabsorbed portion of the drug (approximately 97%) is…
Indications
Worked on MYCIFRADIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.